Timing of bevacizumab administration after biopsy for unresectable newly diagnosed glioblastoma

BACKGROUND: Recent studies have revealed that bevacizumab (BEV) can improve the survival of patients with newly diagnosed unresectable glioblastoma (GBM) with poor performance status. For patients who develop early clinical deterioration, early initiation of BEV would be beneficial. However, the saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuda, Masahide, Kohzuki, Hidehiro, Tsurubuchi, Takao, Ishikawa, Eiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Scientific Scholar 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805652/
https://www.ncbi.nlm.nih.gov/pubmed/36600767
http://dx.doi.org/10.25259/SNI_959_2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805652/
https://www.ncbi.nlm.nih.gov/pubmed/36600767
http://dx.doi.org/10.25259/SNI_959_2022

Ejemplares similares